Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Canada finally opens up data on new drugs and devices.

Lexchin J, Herder M, Doshi P.

BMJ. 2019 Apr 17;365:l1825. doi: 10.1136/bmj.l1825. No abstract available.

PMID:
30996020
2.

Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017.

Doshi P, Spence O, Kuzucan A, Powers JH 3rd.

JAMA Intern Med. 2019 Mar 4. doi: 10.1001/jamainternmed.2018.7040. [Epub ahead of print] No abstract available.

PMID:
30830158
3.

The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?

Doshi P, Sieluk J, Hung A.

J Am Pharm Assoc (2003). 2019 Mar - Apr;59(2):195-201. doi: 10.1016/j.japh.2018.12.003. Epub 2019 Jan 17.

PMID:
30661956
4.

When to include clinical study reports and regulatory documents in systematic reviews.

Jefferson T, Doshi P, Boutron I, Golder S, Heneghan C, Hodkinson A, Jones M, Lefebvre C, Stewart LA.

BMJ Evid Based Med. 2018 Dec;23(6):210-217. doi: 10.1136/bmjebm-2018-110963. Epub 2018 Oct 11.

PMID:
30309870
5.

Challenges of independent assessment of potential harms of HPV vaccines.

Jørgensen L, Doshi P, Gøtzsche P, Jefferson T.

BMJ. 2018 Sep 24;362:k3694. doi: 10.1136/bmj.k3694. No abstract available.

PMID:
30249615
6.

EMA scales back transparency initiatives because of workload.

Doshi P.

BMJ. 2018 Aug 14;362:k3513. doi: 10.1136/bmj.k3513. No abstract available.

PMID:
30108101
7.

The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors.

Hodkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, Doshi P, Heneghan C, Jefferson T, Boutron I, Stewart L.

Syst Rev. 2018 Aug 8;7(1):117. doi: 10.1186/s13643-018-0766-x.

8.

Patient consent to publication and data sharing in industry and NIH-funded clinical trials.

Spence O, Onwuchekwa Uba R, Shin S, Doshi P.

Trials. 2018 May 3;19(1):269. doi: 10.1186/s13063-018-2651-2.

9.

Restoring biomedical literature with RIAT.

Doshi P, Shamseer L, Jones M, Jefferson T.

BMJ. 2018 Apr 26;361:k1742. doi: 10.1136/bmj.k1742. No abstract available.

PMID:
29700000
10.

EMA recommendation on hydroxyethyl starch solutions obscured controversy.

Doshi P.

BMJ. 2018 Mar 20;360:k1287. doi: 10.1136/bmj.k1287. No abstract available.

PMID:
29559433
11.

Correction to: Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol.

Mayo-Wilson E, Hutfless S, Li T, Gresham G, Fusco N, Ehmsen J, Heyward J, Vedula S, Lock D, Haythornthwaite J, Payne JL, Cowley T, Tolbert E, Rosman L, Twose C, Stuart EA, Hong H, Doshi P, Suarez-Cuervo C, Singh S, Dickersin K.

Syst Rev. 2018 Mar 19;7(1):48. doi: 10.1186/s13643-018-0711-z.

12.

Correction to: Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review.

Mayo-Wilson E, Hutfless S, Li T, Gresham G, Fusco N, Ehmsen J, Heyward J, Vedula S, Lock D, Haythornthwaite J, Payne JL, Cowley T, Tolbert E, Rosman L, Twose C, Stuart EA, Hong H, Doshi P, Suarez-Cuervo C, Singh S, Dickersin K.

Alzheimers Res Ther. 2018 Feb 16;10(1):20. doi: 10.1186/s13195-018-0351-5.

13.

CDC tightens controls on scientists' communication with news media.

Doshi P.

BMJ. 2018 Feb 14;360:k675. doi: 10.1136/bmj.k675. No abstract available.

PMID:
29444880
14.

FDA to begin releasing clinical study reports in pilot programme.

Doshi P.

BMJ. 2018 Jan 23;360:k294. doi: 10.1136/bmj.k294. No abstract available.

PMID:
29363507
15.

Noninferiority Trials.

Doshi P, Spence O, Powers JH III.

N Engl J Med. 2018 Jan 18;378(3):304. doi: 10.1056/NEJMc1714668. No abstract available.

PMID:
29345881
16.

The unofficial vaccine educators: are CDC funded non-profits sufficiently independent?

Doshi P.

BMJ. 2017 Nov 7;359:j5104. doi: 10.1136/bmj.j5104. No abstract available.

PMID:
29113985
17.

The problem with US website for collecting adverse events after vaccination is resolved.

Doshi P.

BMJ. 2017 Sep 8;358:j4164. doi: 10.1136/bmj.j4164. No abstract available.

PMID:
28887299
18.

Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy.

Mayo-Wilson E, Li T, Fusco N, Bertizzolo L, Canner JK, Cowley T, Doshi P, Ehmsen J, Gresham G, Guo N, Haythornthwaite JA, Heyward J, Hong H, Pham D, Payne JL, Rosman L, Stuart EA, Suarez-Cuervo C, Tolbert E, Twose C, Vedula S, Dickersin K.

J Clin Epidemiol. 2017 Nov;91:95-110. doi: 10.1016/j.jclinepi.2017.07.014. Epub 2017 Aug 24. Review.

19.

Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011.

Doshi P, Hur P, Jones M, Albarmawi H, Jefferson T, Morgan DJ, Spears PA, Powers JH 3rd.

JAMA Intern Med. 2017 Oct 1;177(10):1452-1459. doi: 10.1001/jamainternmed.2017.3820.

20.

"Independent" reanalysis of landmark starch solutions trial was published by original authors.

Doshi P.

BMJ. 2017 Jul 21;358:j3552. doi: 10.1136/bmj.j3552. No abstract available. Erratum in: BMJ. 2017 Aug 8;358:j3800.

PMID:
28733454
21.

US government website for collecting adverse events after vaccination is inaccessible to most users.

Doshi P.

BMJ. 2017 May 19;357:j2449. doi: 10.1136/bmj.j2449. No abstract available.

PMID:
28526773
22.

Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated Patients.

Jones M, Del Mar C, Doshi P.

Clin Infect Dis. 2017 Sep 15;65(6):1050. doi: 10.1093/cid/cix425. No abstract available.

PMID:
28505232
23.

Pharmacists can help to end direct-to-consumer advertising.

Kuzucan A, Doshi P, Zito JM.

Am J Health Syst Pharm. 2017 May 15;74(10):640-642. doi: 10.2146/ajhp160927. No abstract available.

PMID:
28483941
24.

The wider role of regulatory scientists.

Doshi P, Godlee F.

BMJ. 2017 Apr 27;357:j1991. doi: 10.1136/bmj.j1991. No abstract available.

PMID:
28450290
25.

Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.

Spelsberg A, Prugger C, Doshi P, Ostrowski K, Witte T, Hüsgen D, Keil U; Working Group on Health and Working Group on Freedom of Information, Transparency International Deutschland eV.

BMJ. 2017 Feb 7;356:j337. doi: 10.1136/bmj.j337.

26.

Medical response to Trump requires truth seeking and respect for patients.

Doshi P.

BMJ. 2017 Feb 7;356:j661. doi: 10.1136/bmj.j661. No abstract available.

PMID:
28174155
27.

ADHD medications and cardiovascular adverse events in children and adolescents: cross-national comparison of risk communication in drug labeling.

Sieluk J, Palasik B, dosReis S, Doshi P.

Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):274-284. doi: 10.1002/pds.4164. Epub 2017 Jan 13.

PMID:
28083936
28.

For-profit Uses of Real-World Data: What Would Frances Kelsey Do?

Zito JM, Doshi P.

Med Care. 2016 Dec;54(12):1045-1047. No abstract available.

PMID:
27846130
29.

Is this trial misreported? Truth seeking in the burgeoning age of trial transparency.

Doshi P.

BMJ. 2016 Oct 24;355:i5543. doi: 10.1136/bmj.i5543. No abstract available.

PMID:
27777221
30.

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.

Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T.

Health Technol Assess. 2016 May;20(42):1-242. doi: 10.3310/hta20420. Review.

31.

Convicting Zika.

Doshi P.

BMJ. 2016 Apr 7;353:i1847. doi: 10.1136/bmj.i1847. No abstract available.

PMID:
27056643
32.

Update: New England Journal of Medicine publishes correction to 2012 CHEST trial of hydroxyethyl starch versus colloids.

Doshi P.

BMJ. 2016 Mar 21;352:i1571. doi: 10.1136/bmj.i1571. No abstract available.

PMID:
27001086
33.

Neuraminidase Inhibitors and Influenza Infection.

Doshi P, Jefferson T.

JAMA Intern Med. 2016 Mar;176(3):415-6. doi: 10.1001/jamainternmed.2016.0016. No abstract available.

PMID:
26954053
34.

Data too important to share: do those who control the data control the message?

Doshi P.

BMJ. 2016 Mar 2;352:i1027. doi: 10.1136/bmj.i1027. No abstract available.

PMID:
26936297
35.
36.

Oseltamivir for influenza.

Doshi P, Heneghan C, Jefferson T.

Lancet. 2016 Jan 9;387(10014):124. doi: 10.1016/S0140-6736(15)01282-9. Epub 2016 Jan 8. No abstract available.

PMID:
26841993
37.

Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing.

Doshi P.

BMJ. 2016 Jan 6;352:h6849. doi: 10.1136/bmj.h6849. No abstract available.

PMID:
26740024
38.

The Untapped Potential of Pharmacy Leaflets for Informing Patients About Drug Benefits and Risks.

Hung A, Sieluk J, Doshi P.

JAMA Intern Med. 2016 Jan;176(1):11-2. doi: 10.1001/jamainternmed.2015.6656. No abstract available.

PMID:
26618769
39.

Visualising childhood vaccination schedules across G8 countries.

Doshi P, Stahl-Timmins W, Merino JG, Simpkins C.

BMJ. 2015 Nov 15;351:h5966. doi: 10.1136/bmj.h5966. No abstract available.

PMID:
26568637
40.

Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol.

Mayo-Wilson E, Hutfless S, Li T, Gresham G, Fusco N, Ehmsen J, Heyward J, Vedula S, Lock D, Haythornthwaite J, Payne JL, Cowley T, Tolbert E, Rosman L, Twose C, Stuart EA, Hong H, Doshi P, Suarez-Cuervo C, Singh S, Dickersin K.

Syst Rev. 2015 Nov 2;4:143. doi: 10.1186/s13643-015-0134-z. Erratum in: Alzheimers Res Ther. 2018 Feb 16;10 (1):20. Syst Rev. 2018 Mar 19;7(1):48.

41.

North American regulatory agencies can and should make clinical trial data publicly available.

Persaud N, Doshi P.

CMAJ. 2016 Feb 2;188(2):96-97. doi: 10.1503/cmaj.150679. Epub 2015 Oct 13. No abstract available.

42.

Oseltamivir for influenza.

Doshi P, Heneghan C, Jefferson T.

Lancet. 2015 Sep 19;386(9999):1134-5. doi: 10.1016/S0140-6736(15)00202-0. No abstract available.

PMID:
26461899
43.

Are manufacturers sharing data as promised?

Mayo-Wilson E, Doshi P, Dickersin K.

BMJ. 2015 Sep 25;351:h4169. doi: 10.1136/bmj.h4169. No abstract available.

PMID:
26407814
44.
45.

21st century cures: is US medicines bill a colossal mistake?

Doshi P.

BMJ. 2015 Jul 23;351:h4013. doi: 10.1136/bmj.h4013. No abstract available.

PMID:
26205953
46.

FDA drug summaries: a simplification too far?

Doshi P.

BMJ. 2015 Jun 12;350:h3135. doi: 10.1136/bmj.h3135. No abstract available.

PMID:
26070648
47.

No vote in US Congress on proposal to create new pathway for approving antibiotics.

Doshi P.

BMJ. 2015 Mar 31;350:h1767. doi: 10.1136/bmj.h1767. No abstract available.

PMID:
25829197
48.

Speeding new antibiotics to market: a fake fix?

Doshi P.

BMJ. 2015 Mar 25;350:h1453. doi: 10.1136/bmj.h1453. No abstract available.

PMID:
25814536
49.

The evidence base for new drugs.

Doshi P, Jefferson T.

BMJ. 2015 Mar 2;350:h952. doi: 10.1136/bmj.h952. No abstract available.

PMID:
25731767
50.

Safety and efficacy of inactivated influenza vaccines in children.

Collignon P, Doshi P, Del Mar C, Jefferson T.

Clin Infect Dis. 2015 Feb 1;60(3):489. doi: 10.1093/cid/ciu835. Epub 2014 Oct 23. No abstract available.

PMID:
25344541

Supplemental Content

Loading ...
Support Center